Drug intelligence / Profile preview

AD-224B

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-224B is a small molecule antihypertensive drug developed by Addpharma for the treatment of essential hypertension. It is part of a series of related compounds (including AD-224A and others) currently in late-stage clinical development. The precise mechanism of action has not been publicly defined as of the latest updates. Clinical trials are ongoing to evaluate its efficacy and safety in patients with essential hypertension, with Phase 3 studies underway in South Korea and the United States[1][2][3].

Beyond the preview

Go deeper on AD-224B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-224B.

Explore the full profile